Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 2
2009 1
2010 2
2011 4
2012 2
2013 1
2014 3
2015 8
2016 6
2017 9
2018 7
2020 1
2021 4
2022 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

42 results

Results by year

Filters applied: . Clear all
Page 1
Peginterferon beta-1a concentrations in breast milk of lactating multiple sclerosis patients.
Houtchens M, Mahlanza T, Ciplea AI, Manieri MC, Ramia NF, Zhao Y, England S, Avila R, Altincatal A, Vignos M, Hellwig K. Houtchens M, et al. Mult Scler Relat Disord. 2022 Apr;60:103700. doi: 10.1016/j.msard.2022.103700. Epub 2022 Feb 20. Mult Scler Relat Disord. 2022. PMID: 35263702
We examined concentrations of peginterferon beta-1a in breast milk of lactating patients with multiple sclerosis (MS) receiving peginterferon beta-1a as their postpartum disease-modifying therapy. METHODS: After completion of titration to …
We examined concentrations of peginterferon beta-1a in breast milk of lactating patients with multiple sclerosis (MS) r …
Peginterferon beta-1a: a review of its use in patients with relapsing-remitting multiple sclerosis.
Hoy SM. Hoy SM. CNS Drugs. 2015 Feb;29(2):171-9. doi: 10.1007/s40263-015-0227-1. CNS Drugs. 2015. PMID: 25666445 Review.
In ADVANCE, peginterferon beta-1a had an acceptable tolerability profile that was consistent with that of established interferon beta treatments. ...In the absence of head-to-head studies, definitive conclusions on the comparative efficacy and tolerability of …
In ADVANCE, peginterferon beta-1a had an acceptable tolerability profile that was consistent with that of established i …
Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE.
Kieseier BC, Arnold DL, Balcer LJ, Boyko AA, Pelletier J, Liu S, Zhu Y, Seddighzadeh A, Hung S, Deykin A, Sheikh SI, Calabresi PA. Kieseier BC, et al. Mult Scler. 2015 Jul;21(8):1025-35. doi: 10.1177/1352458514557986. Epub 2014 Nov 28. Mult Scler. 2015. PMID: 25432952 Free PMC article. Clinical Trial.
METHODS: Patients were randomized to placebo or 125 g peginterferon beta-1a every 2 or 4 weeks. For Year 2 (Y2), patients originally randomized to placebo were re-randomized to peginterferon beta-1a every 2 weeks or every 4 weeks. Patient …
METHODS: Patients were randomized to placebo or 125 g peginterferon beta-1a every 2 or 4 weeks. For Year 2 (Y2), patien …
Pharmacokinetics/pharmacodynamics by race: Analysis of a peginterferon beta-1a phase 1 study.
Zhao Y, Mokliatchouk O, Ramia NF, Naylor ML, Butts CL. Zhao Y, et al. Med. 2022 Sep 9;3(9):612-621.e3. doi: 10.1016/j.medj.2022.06.006. Epub 2022 Jul 18. Med. 2022. PMID: 35853458 Free article. Clinical Trial.
METHODS: Peginterferon beta-1a (125 mug) was administered by subcutaneous or intramuscular injection, followed by a washout period before a second injection using the alternative method. ...CONCLUSIONS: No clinically meaningful differences were identified bet …
METHODS: Peginterferon beta-1a (125 mug) was administered by subcutaneous or intramuscular injection, followed by a was …
Peginterferon beta-1a for the treatment of relapsing multiple sclerosis: A case series.
Hendin BA. Hendin BA. Mult Scler Relat Disord. 2018 Nov;26:33-36. doi: 10.1016/j.msard.2018.08.012. Epub 2018 Aug 13. Mult Scler Relat Disord. 2018. PMID: 30216756
The most commonly reported adverse effects are flu-like symptoms and injection site reactions. The most recent addition to the class is peginterferon beta-1a, which is administered subcutaneously every 2 weeks. ...Herein I present 3 cases of patients who eith …
The most commonly reported adverse effects are flu-like symptoms and injection site reactions. The most recent addition to the class is p …
Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study.
Hu X, Cui Y, White J, Zhu Y, Deykin A, Nestorov I, Hung S. Hu X, et al. Br J Clin Pharmacol. 2015 Mar;79(3):514-22. doi: 10.1111/bcp.12521. Br J Clin Pharmacol. 2015. PMID: 25265472 Free PMC article. Clinical Trial.
AIMS: To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneous peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis (RRMS) in the phase 3 ADVANCE study (n = 1512). ...Patients randomized to peginterfer …
AIMS: To evaluate the pharmacokinetics (PK) and pharmacodynamics (PD) of subcutaneous peginterferon beta-1a in p …
Pharmacokinetics, pharmacodynamics, and safety of peginterferon beta-1a in subjects with normal or impaired renal function.
Hu X, Seddighzadeh A, Stecher S, Zhu Y, Goyal J, Matson M, Marbury T, Smith W, Nestorov I, Hung S. Hu X, et al. J Clin Pharmacol. 2015 Feb;55(2):179-88. doi: 10.1002/jcph.390. Epub 2014 Sep 23. J Clin Pharmacol. 2015. PMID: 25187030 Free PMC article. Clinical Trial.
Peginterferon beta-1a was efficacious in a Phase 3 relapsing multiple sclerosis trial, and its safety profile was consistent with other beta interferons. ...Neopterin baseline, peak concentration, and AUC increased as renal function decreased. Peginterfero …
Peginterferon beta-1a was efficacious in a Phase 3 relapsing multiple sclerosis trial, and its safety profile was consi …
Peginterferon beta-1a versus other self-injectable disease-modifying therapies in the treatment of relapsing-remitting multiple sclerosis in Scotland: a cost-effectiveness analysis.
Hernandez L, Guo S, Toro-Diaz H, Carroll S, Syed Farooq SF. Hernandez L, et al. J Med Econ. 2017 Mar;20(3):228-238. doi: 10.1080/13696998.2016.1247712. Epub 2016 Nov 4. J Med Econ. 2017. PMID: 27730845 Free article.
AIMS: Peginterferon beta-1a 125 mcg administered subcutaneously every 2 weeks, a new disease-modifying therapy (DMT) for relapsing-remitting multiple sclerosis (RRMS), was approved in January 2015 by the Scottish Medicines Consortium. ...Deterministic and pro …
AIMS: Peginterferon beta-1a 125 mcg administered subcutaneously every 2 weeks, a new disease-modifying therapy (DMT) fo …
42 results